BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 25678112)

  • 21. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
    Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
    Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.
    Liang Y; Tian B; Zhang J; Li K; Wang L; Han J; Wu Z
    Int J Nanomedicine; 2017; 12():1699-1715. PubMed ID: 28280336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
    Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
    Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
    Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy.
    Wang Q; Zhu X; Wu Z; Sun T; Huang W; Wang Z; Ding X; Jiang C; Li F
    J Mater Chem B; 2020 Mar; 8(12):2410-2417. PubMed ID: 32100811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-Delivery of Gemcitabine and Mcl-1 SiRNA via Cationic Liposome-Based System Enhances the Efficacy of Chemotherapy in Pancreatic Cancer.
    Wang Y; Gao F; Jiang X; Zhao X; Wang Y; Kuai Q; Nie G; He M; Pan Y; Shi W; Ren S; Yu Q
    J Biomed Nanotechnol; 2019 May; 15(5):966-978. PubMed ID: 30890228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
    Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
    Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment.
    Han H; Wang J; Chen T; Yin L; Jin Q; Ji J
    J Colloid Interface Sci; 2017 Dec; 507():217-224. PubMed ID: 28800445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice.
    Kattel K; Mondal G; Lin F; Kumar V; Mahato RI
    Mol Pharm; 2017 May; 14(5):1365-1372. PubMed ID: 27798825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.
    Lin L; Fan Y; Gao F; Jin L; Li D; Sun W; Li F; Qin P; Shi Q; Shi X; Du L
    Theranostics; 2018; 8(7):1923-1939. PubMed ID: 29556365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-Delivery of Gemcitabine and Honokiol by Lipid Bilayer-Coated Mesoporous Silica Nanoparticles Enhances Pancreatic Cancer Therapy via Targeting Depletion of Tumor Stroma.
    Liu D; Wang L; Li H; Li D; Zhou J; Wang J; Zhang Q; Cai D
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer.
    Khan S; Setua S; Kumari S; Dan N; Massey A; Hafeez BB; Yallapu MM; Stiles ZE; Alabkaa A; Yue J; Ganju A; Behrman S; Jaggi M; Chauhan SC
    Biomaterials; 2019 Jul; 208():83-97. PubMed ID: 30999154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
    Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J
    Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy.
    Li Y; Chen Y; Li J; Zhang Z; Huang C; Lian G; Yang K; Chen S; Lin Y; Wang L; Huang K; Zeng L
    Cancer Sci; 2017 Jul; 108(7):1493-1503. PubMed ID: 28444967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
    Mondal G; Almawash S; Chaudhary AK; Mahato RI
    Mol Pharm; 2017 Sep; 14(9):3121-3133. PubMed ID: 28719220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
    Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
    Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
    Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
    Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy.
    Lu Z; Su J; Li Z; Zhan Y; Ye D
    Drug Dev Ind Pharm; 2017 Jan; 43(1):160-170. PubMed ID: 27553814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.